The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

OKUK Holdings Ltd is a private company limited by shares incorporated in England and Wales. The registered office is Unit 16 Block A, Braintree Enterprise Centre, 46-48 Springwood Drive, Braintree, Essex, CM7 2YN.

The financial statements cover a 14 month period from 1 May 2024 to 30 June 2025 to align its annual financial reporting with its parent company. Therefore the comparative period's financial information is not entirely comparable.

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

The average monthly number of persons (including directors) employed by the company during the period was:

In May 2024 the company was acquired by new owners and 373,175 A Ordinary shares were issued. All shares were subsequently reclassified as Ordinary shares of £1 each.

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006:

The auditor's report was unqualified.

At the year end the company was owed £127 (2024: £127) from IMMY MDx Ltd, a wholly owned subsidiary.

The parent company is Immuno-Mycologics, Inc., 2701 Corporate Centre, Norman, Oklahoma, United States, 73069, which prepares consolidated group financial statements.